News stories about Novavax (NASDAQ:NVAX) have been trending somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novavax earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.8789330353894 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:

Several equities research analysts have issued reports on NVAX shares. Zacks Investment Research raised shares of Novavax from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a research report on Saturday, June 10th. Cantor Fitzgerald set a $2.00 price objective on shares of Novavax and gave the company a “hold” rating in a research report on Monday, May 8th. Piper Jaffray Companies reissued a “hold” rating and issued a $1.50 price objective on shares of Novavax in a research report on Wednesday, July 26th. BidaskClub raised shares of Novavax from a “sell” rating to a “hold” rating in a research report on Thursday, July 27th. Finally, Chardan Capital reissued a “neutral” rating and issued a $1.50 price objective on shares of Novavax in a research report on Thursday, July 27th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $5.61.

Shares of Novavax (NASDAQ:NVAX) opened at 0.9601 on Tuesday. The stock has a 50 day moving average of $1.17 and a 200 day moving average of $1.17. Novavax has a 12 month low of $0.73 and a 12 month high of $8.49. The stock’s market cap is $271.32 million.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.02. The business had revenue of $5.68 million during the quarter, compared to analysts’ expectations of $6.17 million. During the same period in the previous year, the business posted ($0.29) EPS. The company’s revenue for the quarter was up 34.6% compared to the same quarter last year. On average, equities analysts anticipate that Novavax will post ($0.61) earnings per share for the current fiscal year.

In other news, insider Stanley C. Erck purchased 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 11th. The stock was bought at an average price of $0.84 per share, for a total transaction of $42,000.00. Following the completion of the purchase, the insider now directly owns 128,279 shares of the company’s stock, valued at $107,754.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders purchased 107,057 shares of company stock valued at $92,631 in the last quarter. 4.00% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Novavax (NASDAQ:NVAX) Share Price” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/08/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-novavax-nasdaqnvax-share-price.html.

About Novavax

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Insider Buying and Selling by Quarter for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.